Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
19.40
+0.41 (2.16%)
At close: Oct 2, 2026, 4:00 PM EDT
19.40
0.00 (0.00%)
After-hours: Oct 2, 2026, 4:00 PM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $284.00K in the quarter ending June 30, 2026, with 278.67% growth. This brings the company's revenue in the last twelve months to $71.13M, up 23,220.33% year-over-year. In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth.
Revenue (ttm)
$71.13M
Revenue Growth
+23,220.33%
P/S Ratio
30.84
Revenue / Employee
$282,250
Employees
252
Market Cap
2.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| ADMA Biologics | 512.28M |
| Aurinia Pharmaceuticals | 311.51M |
| Vericel | 306.30M |
| Recursion Pharmaceuticals | 54.86M |
| ADARx Pharmaceuticals | 6.13M |
VRDN News
- 10 days ago - Viridian Therapeutics price target raised to $38 from $36 at RBC Capital - TheFly
- 24 days ago - Viridian Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Business Wire
- 1 month ago - Viridian Therapeutics price target raised to $39 from $38 at Truist - TheFly
- 1 month ago - Viridian Therapeutics price target raised to $36 from $35 at RBC Capital - TheFly
- 1 month ago - Viridian Therapeutics reports EPS ($1.05), consensus ($1.03) - TheFly
- 1 month ago - Viridian Therapeutics sees cash runway through profitability - TheFly
- 1 month ago - Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Business Wire